title: A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone.
abstract: The palliative efficacy of strontium-89 chloride has been evaluated in a prospective double-blind crossover study comparing it with stable strontium as placebo in 32 patients with prostate cancer metastatic to bone. Response was assessed 5 weeks after each treatment. 26 patients were evaluable. Complete pain relief was only reported following strontium-89 injection. Statistical comparison between placebo and strontium-89 showed clear evidence of a therapeutic response to strontium-89 compared with only a limited placebo effect (P less than 0.01).
authors.affiliation: Department of Nuclear Medicine, Southampton General Hospital, U.K.
authors.forename: V J
authors.initials: VJ
authors.lastname: Lewington
authors.forename: A J
authors.initials: AJ
authors.lastname: McEwan
authors.forename: D M
authors.initials: DM
authors.lastname: Ackery
authors.forename: R J
authors.initials: RJ
authors.lastname: Bayly
authors.forename: D H
authors.initials: DH
authors.lastname: Keeling
authors.forename: P M
authors.initials: PM
authors.lastname: Macleod
authors.forename: A T
authors.initials: AT
authors.lastname: Porter
authors.forename: M A
authors.initials: MA
authors.lastname: Zivanovic
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000517:prevention & control; D010166:Palliative Care; D010976:Platelet Count / Q000528:radiation effects; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000532:radiotherapy; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
chemical_list: D013326:Strontium Radioisotopes